로딩 중…
StockDiggingStockDigging

Bausch + Lomb Corporation

BLCO· NYSE
CACA
$16.88+0.66%
2026-09-18

Financials

Valuation Metrics

Bausch + Lomb Corporation's Market Cap is $6.02B. At end of 2025 it was $6.04B. Ranked #1230 of 3,121 in US market (top 39%), #819 of 1,658 on NYSE (top 49%), #80 of 205 in Health Care Equipment & Services (top 39%) by Market Cap.

Investment Metrics(as of 2026-09-18)

MetricValue
Size
Market Cap$6.02B
Revenue$5.32B
Net Income$-171M
Total Assets$13.86B
Net Assets$6.38B
Employees13,000
Value
P/B0.94x
P/S1.13x
EV/EBITDA14.51x
FCF Yield2.33%
Profitability
ROE-2.68%
ROA-1.23%
Op. Margin7.14%
Revenue Growth8.75%
Financial Health
Debt Ratio116.30%
Total Debt$5.12B
FCF$140M
Cash$367M
Current Ratio1.55x
Net Debt/EBITDA6.40x
Performance
1Y Return9.75%
1M Return-3.27%
From 52W High-10.78%
1Y MDD-20.11%
Trading
Volume295,994 shares
Trading Value$5M
Per Share
EPS$-0.48
BPS$17.88

Company Info

CEO Brenton L. Saunders
Employees 13,000
HQ Vaughan, CA

Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.